Citations

Clear

2 citation(s) found for "Scott, John David".

Family history of obesity and the influence on physical activity and dietary adherence after bariatric surgery
Fipps, David C. , Holder, Sharon M., Fipps, David C , Schmalz, Dorothy L. , Scott, John David

Mayo Clinic

Journal of Perioperative Practice | July 6, 2021 | Volume: 32 | Issue: 9 | Pages: 230-233

10.1177/17504589211015615 | PMID 34228555 Get It

Background The causes of obesity are multifactorial, with genetic, environmental, behavioural and societal contributions. These factors also affect adherence to diet and exercise after bariatric surgery. The objective of this study was to evaluate changes in perceived obesity-related stigma, exercise and dietary adherence perioperatively as well as what demographic factors most influence the magnitude of these changes. Methods Validated questionnaires regarding perception of stigma and adherence to diet and exercise regimens were administered to 104 bariatric surgery patients preoperatively and postoperatively at three, six and 12 months. Scoring was compared for improvement, and concomitant factors were analysed for effect on magnitude of improvement. Results Our study found overall improvement in perception of stigma as well as adherence to diet and exercise regimens. Those with a family history of obesity had less robust improvement compared to those without a family history of obesity. Those who were Caucasian also did not have as robust of an improvement in their scores. Conclusions Patient perception of obesity-related stigma and adherence to diet and exercise regimens improve after bariatric surgery. However, a patient with a family history of obesity and/or a Caucasian ethnicity may have a less robust improvement in these facets.
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Petrylak, Daniel P. , Tagawa, Scott T. , Eisen, Andrea , Canil, Christina , Burke, John M. , Shaffer, David R. , Pan, Chong‐Xian, Aragon‐Ching, Jeanny B. , Tang, Shande, Zhang, Hui , Cavanaugh, Christopher , Gao, Ling , Walgren, Richard A., Kohli, Manish , Spira, Alexander, Yu, Evan Y., Shaffer, David, Kim, Jenny J, Aragon-Ching, Jeanny B, Quinn, David I, Vogelzang, Nicholas J. , Cavanaugh, Christopher T, Kauh, John S, Chi, Kim N, Sridhar, Srikala S , Spira, Alexander I. , Yu, Evan Y , Kim, Jaeyeon , Quinn, David I , Kauh, John Sae Wook , N., Kim , Tagawa, Scott T , Eisen, Andrea

Mayo Clinic

Journal of Clinical Oncology | March 1, 2016 | Volume: 34 | Issue: 13 | Pages: 1500-1509

10.1200/jco.2015.65.0218 | PMID 26926681 Get It

Purpose This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody) after progression during or within 12 months of platinum-based regimens for patients with locally advanced or metastatic urothelial carcinoma. Patients and Methods Patients were randomly assigned (1:1:1) to receive docetaxel 75 mg/m2 intravenously (IV) on day 1 of a 3-week cycle (arm A), docetaxel 75 mg/m2 IV plus ramucirumab 10 mg/kg IV on day 1 of a 3-week cycle (arm B), or docetaxel 75 mg/m2 IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of a 3-week cycle (arm C). Treatment continued until disease progression or unacceptable toxicity. The primary end point was investigator-assessed progression-free survival (PFS). Results A total of 140 patients were randomly assigned and treated in arms A (n = 45), B (n = 46), or C (n = 49). PFS was significantly longer in arm B compared with arm A (median, 5.4 months; 95% CI, 3.1 to 6.9 months v 2.8 months; 95% CI, 1.9 to 3.6 months; stratified hazard ratio, 0.389; 95% CI, 0.235 to 0.643; P = .0002). Arm C did not experience improved PFS compared with arm A (1.6 months; 95% CI, 1.4 to 2.9; stratified hazard ratio, 0.863; 95% CI, 0.550 to 1.357; P = .5053). The most common grade 3 or worse adverse events (arms A, B, and C) were neutropenia (36%, 33%, and 39%), fatigue (13%, 30%, and 20%), febrile neutropenia (13%, 17%, and 6.1%), and anemia (6.7%, 13%, and 14%, respectively). Conclusion The addition of ramucirumab to docetaxel met the prespecified efficacy end point for prolonging PFS in patients with locally advanced or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation in the phase III setting.